The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis

Veale, DJ, McGonagle, D, McInnes, IB et al. (8 more authors) (2018) The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology. key070. ISSN 1462-0324

Abstract

Metadata

Authors/Creators:
  • Veale, DJ
  • McGonagle, D
  • McInnes, IB
  • Krueger, JG
  • Ritchlin, CT
  • Elewaut, D
  • Kanik, KS
  • Hendrikx, T
  • Berstein, G
  • Hodge, J
  • Telliez, J-B
Copyright, Publisher and Additional Information: (c) The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Keywords: spondyloarthropathies (including psoriatic arthritis); DMARDs; cytokines and inflammatory mediators; bone; gastrointestinal; ligaments and tendons; skin; synovium
Dates:
  • Published: 3 April 2018
  • Accepted: 20 February 2018
  • Published (online): 3 April 2018
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 24 Sep 2018 11:54
Last Modified: 24 Sep 2018 11:54
Status: Published
Publisher: Oxford University Press
Identification Number: https://doi.org/10.1093/rheumatology/key070

Download

Filename: key070.pdf

Licence: CC-BY-NC 4.0

Share / Export

Statistics